Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

Yan, Shunchao; Jiao, Xia; Zou, Huawei; Li, Kai

doi:10.1186/s13000-015-0296-y

Cited by 70 publications

(64 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For this group of patients, chemotherapy is the primary systemic therapy and there is a need for finding new targets for treatment. A prognostic role for Met in TNBC was likewise found in a meta-analysis study about Met [24]. Furthermore, it was found in the pre-menopausal cohort that stromal HGF, but not tumoural HGF, was associated with shorter survival from TNBC, a difference not previously reported.…”

Section: Discussionmentioning

confidence: 58%

See 1 more Smart Citation

Met and its ligand HGF are associated with clinical outcome in breast cancer

et al. 2016

View full text Add to dashboard Cite

Few biomarkers exist to predict radiotherapy response in breast cancer. In vitro studies suggest a role for Met and its ligand HGF. To study this suggested role, MET and HGF gene copy numbers were determined by droplet digital PCR in tumours from 205 pre-menopausal and 184 post-menopausal patients, both cohorts randomised to receive either chemo- or radiotherapy. MET amplification was found in 8% of the patients in both cohorts and HGF amplification in 7% and 6% of the patients in the pre- and post-menopausal cohort, respectively. Met, phosphorylated Met (pMet), and HGF protein expression was determined by immunohistochemistry in the pre-menopausal cohort. Met, pMet, and HGF was expressed in 33%, 53%, and 49% of the tumours, respectively. MET amplification was associated with increased risk of distant recurrence for patients receiving chemotherapy. For the pre-menopausal patients, expression of cytoplasmic pMet and HGF significantly predicted benefit from radiotherapy in terms of loco-regional recurrence. Similar trends were seen for MET and HGF copy gain. In the post-menopausal cohort, no significant association of benefit from radiotherapy with neither genes nor proteins was found. The present results do not support that inhibition of Met prior to radiotherapy would be favourable for pre-menopausal breast cancer, as previously suggested.

show abstract

Section: Discussionmentioning

confidence: 58%

“…In cohort 2, no correlation was found between MET gain and the HER2 positive subtype, which is in agreement with the meta-analysis conducted by Yan et al . [24]. Cohort 1, however, showed an association between MET gain and the HER2 positive subtype.…”

Section: Discussionmentioning

confidence: 99%

Met and its ligand HGF are associated with clinical outcome in breast cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the most common malignant tumor in women, and its incidence has been increasing year on year [1]. In addition, the age of breast cancer onset is decreasing [2].…”

Section: Introductionmentioning

confidence: 99%

LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells

Zhao

Ren

2016

J Breast Cancer

View full text Add to dashboard Cite

PurposeThis study was designed to investigate the role of taurine-upregulated gene 1 (TUG1) in MCF-7 breast cancer cells and the molecular mechanism involved in the regulation of microRNA-9 (miR-9).MethodsThe expression of TUG1 in breast cancer tissues and cells was evaluated using quantitative reverse transcription polymerase chain reaction. Cell viability was examined using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay; cell cycle progression and apoptosis were analyzed using flow cytometry. A dual luciferase reporter assay was used to detect the relationship between TUG1 and miR-9. The expression of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) was measured by western blot.ResultsHigher expression of TUG1 was observed in breast cancer tissues and cell lines than in the corresponding controls. TUG1 knockdown reduced proliferation, suppressed cell cycle progression, and promoted apoptosis of MCF-7 cells. The dual luciferase reporter assay showed that TUG1 could negatively regulate the expression of miR-9. MiR-9 inhibition abrogated the effect of TUG1 knockdown on the proliferation, cell cycle progression, and apoptosis of MCF-7 cells. TUG1 positively regulated the expression of MTHFD2 in breast cancer cells.ConclusionTUG1 knockdown was significantly associated with decreased cell proliferation and it promoted apoptosis of breast cancer cells through the regulation of miR-9.

show abstract

“…This indicates that Met and EGFR are related to the more aggressive subtypes. Indeed, in concordance with other studies, MET and EGFR amplification was more frequently found in TNBC in the postmenopausal cohort [44,161,162]. MET gain was found to be correlated with the HER2-like subtype in the pre-menopausal cohort, in agreement with a 2013 study [163].…”

Section: Genes and Proteins In Relation To Clinicopathological Characsupporting

confidence: 80%

“…Contrarily, no correlation was found between MET gain and HER2-like disease in the postmenopausal cohort, which was likewise shown in a meta-analysis of multiple studies [162]. Interestingly, cytoplasmic pMet tended to be more abundant in the less- results [104].…”

Section: Genes and Proteins In Relation To Clinicopathological Characmentioning

confidence: 70%

The receptor tyrosine kinase Met and the protein tyrosinephosphatase PTPN2 in breast cancer

Veenstra¹

View full text Add to dashboard Cite

This thesis aimed to explore possible prognostic and predictive biomarkers in different subtypes and study their role in breast cancer. To this aid, breast cancer tumours of pre-and post-menopausal patients enrolled in two cohorts were analysed for gene copy numbers and expression of proteins involved in cell proliferation. Gene copy numbers of receptor tyrosine kinases MET and EGFR, Met's ligand HGF, and protein tyrosine phosphatase PTPN2 were determined by droplet digital PCR or quantitative PCR in both cohorts. Met, phosphorylated Met (pMet), HGF, and PTPN2 protein expression levels were analysed with immunohistochemical staining in the pre-menopausal cohort. Moreover, the role of the aforementioned proteins was investigated in breast cancer cell lines.Amplification of MET, HGF, and EGFR in breast tissues was found to be low (5-8%). These three genes, all located on chromosome 7, were found to be strongly correlated with each other and to be associated with shortened distant recurrence-free survival. High protein expression of Met, pMet, and HGF was found in 33%, 53%, and 49% of the breast tumours. MET and EGFR were found to be more often amplified in TNBC disease, correlating with worse survival.Moreover, stromal expression of HGF was associated with shorter survival in TNBC. EGF stimulation in TNBC cell line MDA-MB-468 led to inhibited cell

show abstract

Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

Cited by 70 publications

References 44 publications

Met and its ligand HGF are associated with clinical outcome in breast cancer

Met and its ligand HGF are associated with clinical outcome in breast cancer

LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells

The receptor tyrosine kinase Met and the protein tyrosinephosphatase PTPN2 in breast cancer

Contact Info

Product

Resources

About